Search clinical trials for: Zytiga

Total 135 results

Mayo Clinic

Not yet recruiting

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer

Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Prostatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States, Puerto Rico, Israel, Australia, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic

Canada, United States, Israel, Puerto Rico, Taiwan, Korea, Republic of, Australia, Chile, China, France, Norway
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Turkey, Sw...
Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States
Leiden University Medical Center
Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Anticancer...

Recruiting

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)

Prostatic Neoplasms, Castration-Resistant

Australia, Netherlands
AstraZeneca
Bayer

Recruiting

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Metastatic Prostate Cancer

Italy, United Kingdom, Australia, United States
Fudan University

Recruiting

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Prostate Cancer

China
M.D. Anderson Cancer Center
AstraZeneca

Recruiting

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Bladder Cancer | Urothelial Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States
University of Michigan Rogel Cancer Center

Recruiting

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Prostate Cancer | Oligometastatic Disease | Castrate Sensitive Prostate Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma

United States
Myovant Sciences GmbH

Recruiting

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate Cancer

United States
University of Washington
Blue Earth Diagnostics

Recruiting

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Prostate Adenocarcinoma

United States
Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
Martha Mims

Recruiting

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (APRE)

Prostate Cancer | Prostate Cancer Metastatic

United States
University of Texas Southwestern Medical Center
National Institutes of Health Clinical Center (CC); University of Michigan; Children... and other collaborators

Not yet recruiting

Androgen Reduction in Congenital Adrenal Hyperplasia (ARCH)

Congenital Adrenal Hyperplasia

United States
Northwestern University

Recruiting

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Active, not recruiting

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Metastatic Castration-resistant Prostate Cancer

China
Medical College of Wisconsin

Active, not recruiting

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Carcinoma Metastatic in the Bone

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Prostatic Neoplasms

United States, Australia, France, Germany, United Kingdom, Belgium, Spain, Argentina, South Africa, Japan, Canada, Netherlands, Korea, Republic of, Brazil, Russian Federation, Mexico
Janssen Biotech, Inc.

Active, not recruiting

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Prostate Cancer | Prostatic Neoplasm

United States
Dana-Farber Cancer Institute
Janssen Pharmaceutica

Active, not recruiting

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute

Active, not recruiting

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Prostate Cancer

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Metastatic Castration-resistant Prostate Cancer

China
pharmaand GmbH
Foundation Medicine

Active, not recruiting

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

Metastatic Castration Resistant Prostate Cancer

United States, Canada, Spain, France, Australia, Ireland, Belgium, Denmark, United Kingdom, Germany, Israel, Italy
VA Office of Research and Development

Active, not recruiting

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Newly Diagnosed Oligometastatic Prostate Cancer

United States
University of Texas Southwestern Medical Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Suspended

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

Congenital Adrenal Hyperplasia

United States
Pfizer
Astellas Pharma Inc

Active, not recruiting

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

Prostatic Neoplasms

United States
Epizyme, Inc.

Active, not recruiting

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (CELLO-1)

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Spain, Belgium
Pfizer
Astellas Pharma Inc

Active, not recruiting

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States, Italy, Spain, Belgium, Canada, France, Korea, Republic of, United Kingdom, Brazil, Czechia, Turkey, Australia, Chile, Germany, Japan, Netherlands, Slovakia
OHSU Knight Cancer Institute
Janssen Scientific Affairs, LLC; Oregon Health and Science University

Active, not recruiting

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
Pfizer
Astellas Pharma Inc

Active, not recruiting

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Prostatic Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Prostate Cancer | Advanced Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Jonsson Comprehensive Cancer Center
Janssen Inc.

Active, not recruiting

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation

United States
Veru Inc.

Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERACITY)

Metastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic Cancer

United States
Bukwang Pharmaceutical
Dyna Therapeutics

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

Prostate Cancer

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, New Zealand
University of Chicago

Active, not recruiting

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
Daniel George, MD
Janssen Scientific Affairs, LLC

Active, not recruiting

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer (PANTHER)

Prostate Cancer

United States
Tavanta Therapeutics

Completed

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Metastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
AstraZeneca

Active, not recruiting

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)

Hormone-Sensitive Prostate Cancer

United States, Belgium, Spain, Canada, Poland, Argentina, India, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Germany, Korea, Republic of, Brazil, Mexico, Peru, Philippines, China, United Kingdom, Hong Kong, Israel, ... and more

Search clinical trials for: Zytiga

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations